Abstract Details

Title Comparison of the Location of Cortical Grey Matter Lesions, Using DIR and PSIR

Topic MS and Related Diseases

Presentation(s) S51 - (-)

Poster/Presentation
Number 002

Objective

Background Detection of multiple sclerosis (MS) cortical gray matter (CGM) lesions has improved using double inversion recovery (DIR) scans. CGM lesions on DIR can be classified as intracortical (IC: involving cortex only) or leucocortical (LC: involving cortex and adjacent while matter). A high-resolution phase sensitive inversion recovery (PSIR) sequence, which has been shown to identify three times more lesions that DIR, has the potential to localize CGM lesions more accurately than DIR. Accurate localization of CGM lesions is important for diagnosis and predicting disease progression.

Design/Methods DIR (with 1x1x3mm resolution) and PSIR (0.5x0.5x2mm resolution) scans were obtained on a 3T Philips Achieva MRI scanner in 10 MS patients. The higher resolution of PSIR, allowed the definition of 2 additional subgroups: juxtacortical (JC: white matter only, touching the cortex) and white matter (WM: white matter only not touching the cortex).

Results 120 CGM lesions, (43 (36%) IC and 77 (64%) LC) were identified on DIR. Of the 43 IC lesions, 25 (58%) were confirmed on PSIR, and 18 (42%) were reclassified (13 LC, 4 JC, 1 WM). Of the 77 (64%) LC DIR lesions, 24 (31%) were confirmed as LC on PSIR, and 53(69%) were reclassified (19 IC, 25 JC, 9 WM).

Conclusions The higher PSIR resolution enabled the introduction of 2 more subgroups. The resulting more detailed analysis led to a reclassification of 59% (71/120) of lesions, thereby reducing the number of CGM lesions identified on DIR by 32.5% (39/120).

Authors/Disclosures
Varun Sethi, MD, PhD (Imperial College Health Trust,) PRESENTER	No disclosure on file
Declan T. Chard	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
David H. Miller, MD, MBChB, FRCP (Univ Dept of Clinical Neuro)	No disclosure on file
	No disclosure on file
Douglas L. Arnold, MD, FAAN (Montreal Neurological Institute, McGill Univ)	Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Frequency Therapeutics. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xfacto communications. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Find therapeutics. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Idorsia. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kiniksa. Dr. Arnold has stock in NeuroRx.

��ɫ��

��ɫ��